Compare Amphastar Pharmaceuticals Inc (AMPH) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Snap On Incorporated trades at $401.94 (market cap $20.82B). The key difference: Snap On Incorporated is far larger — about 25.2× Amphastar Pharmaceuticals Inc's market cap, and Snap On Incorporated pays a 2.43% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SNA | |
|---|---|---|
Market Cap | $826.08M | $20.82B |
Sector | Health | Technology |
52-Week High | $30.81 | $413.62 |
52-Week Low | $16.87 | $313.01 |
Enterprise Value | $1.22B | $20.34B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Snap-on Incorporated (SNA) trades at $401.94, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong profitability with a 19.6% net income margin and a 17.83% ROE for 2025. Recent strategic acquisitions, including Diesel Laptops for $100 million, aim to expand its heavy-duty diagnostics capabilities, while a $500 million share repurchase authorization and consistent dividends underscore shareholder returns.
The outlook is positive, supported by operational agility and steady cash flow growth, with net cash flow rising to $318 million projected for 2026. Key risks include muted revenue growth and margin pressures, as seen in the Q1 2026 earnings miss. Investor sentiment is cautiously optimistic, with 65% of analysts rating the stock a buy, but competitive and macroeconomic headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
